Core Viewpoint - The State Council has issued an implementation opinion to accelerate the cultivation and opening of application scenarios, marking a systematic deployment at the national level for the first time [1] Group 1: Definition and Importance of Scenarios - Scenarios are defined as specific contexts for the innovative application of new technologies, products, and business models, serving as a bridge between technology and industry [2] - The cultivation of scenarios is aimed at leveraging China's large market and diverse application scenarios to create experimental fields for new technologies and products, thus accelerating their industrialization [2] Group 2: Multi-Party Efforts in Scenario Cultivation - The Ministry of Industry and Information Technology has supported 46 cities in promoting digital and green technologies, and has implemented insurance compensation policies for major technological equipment [3] - Anhui Province plans to establish nearly 300 application scenarios by the end of this year and aims for 1,000 by 2027, focusing on quantum information [3] Group 3: Role of Central Enterprises - Central enterprises are seen as a rich source for scenario supply, providing over 400 pilot services and collaborating with various entities to enhance technological innovation and industrial renewal [4] Group 4: Future Directions and Mechanisms - The Ministry of Science and Technology will focus on key core technology breakthroughs and the efficient transformation of major technological achievements to drive new industrial momentum [6] - The State-owned Assets Supervision and Administration Commission aims to enhance the supply of high-value scenarios and broaden the scope of scenario opening, encouraging participation from various business entities [6] Group 5: Implementation and Coordination - Effective implementation of the opinion requires strengthening collaboration, highlighting key areas, and improving mechanisms to support the establishment of a diverse scenario cultivation system [7]

Core Insights - The State Council has issued a systematic deployment for scene cultivation and opening, marking a significant step in promoting high-quality development through innovative applications of new technologies and products [1][2] Group 1: Definition and Importance of Scenes - "Scenes" are defined as specific contexts for the innovative application of new technologies, products, and business models, serving as a bridge between technology and industry [2] - The cultivation of scenes is seen as a key resource for innovation, facilitating the transformation of technological achievements into productive forces [2] Group 2: Implementation and Support - The Ministry of Industry and Information Technology has supported 46 cities in promoting smart and green technologies, with plans to establish 63 provincial future industry pilot zones [3] - Various provinces, such as Anhui and Guangdong, are actively developing application scenarios, with Anhui aiming to implement nearly 300 scenarios by the end of the year and 1,000 by 2027 [3][4] Group 3: Role of Central Enterprises - Central enterprises are identified as significant contributors to scene supply, with 190 pilot verification platforms providing over 400 services to various sectors [4] - The State-owned Assets Supervision and Administration Commission is encouraging the participation of private and small enterprises in scene construction [5] Group 4: Future Directions and Coordination - The focus will be on strengthening core technology breakthroughs and enhancing the role of enterprises in technological innovation [5] - The implementation of the opinions will require coordinated efforts to expand market access and explore new market configurations for innovative elements [6]

Core Viewpoint - The stock of Haishike has shown a significant increase of 64.01% year-to-date, despite a recent decline of 2.96% over the past five trading days, indicating volatility in its performance [1][2]. Financial Performance - For the period from January to September 2025, Haishike achieved a revenue of 3.3 billion yuan, representing a year-on-year growth of 19.95%. However, the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2]. - Cumulatively, Haishike has distributed 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Haishike increased by 12.87% to 12,900, with an average of 37,342 circulating shares per shareholder, down by 11.40% [2]. - The top ten circulating shareholders include several institutional investors, with notable increases in holdings from entities such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited [3]. Stock Market Activity - On November 10, Haishike's stock price rose by 2.04% to 54.09 yuan per share, with a trading volume of 123 million yuan and a turnover rate of 0.48%. The total market capitalization reached 60.576 billion yuan [1]. - The net outflow of main funds was 237,700 yuan, while large orders showed a mixed trend with 9.09 million yuan in purchases and 10.61 million yuan in sales [1]. Business Overview - Haishike Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sales of chemical pharmaceuticals, with its main revenue sources being anesthetic products (39.81%), cooperative product-related income (23.59%), and other therapeutic areas [1]. - The company is categorized under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors including Helicobacter pylori, hypertension treatment, and innovative drugs [1].

Core Viewpoint - Shenzhou Cell's stock has shown significant volatility, with a year-to-date increase of 40.52%, but recent declines in the short term raise concerns about its performance [1][2]. Company Overview - Shenzhou Cell, established on April 23, 2007, and listed on June 22, 2020, is based in Beijing and focuses on the research and commercialization of biopharmaceutical products for various diseases, including cancer and autoimmune disorders [1]. - The company's main business revenue is derived entirely from product sales [1]. Financial Performance - For the period from January to September 2025, Shenzhou Cell reported a revenue of 1.312 billion yuan, a year-on-year decrease of 32.27%, and a net profit attributable to shareholders of -251 million yuan, reflecting a significant decline of 267.17% [2]. - As of September 30, 2025, the number of shareholders increased by 40.96% to 13,700, while the average circulating shares per person decreased by 29.06% to 32,390 shares [2]. Stock Market Activity - As of November 10, Shenzhou Cell's stock price was 50.91 yuan per share, with a market capitalization of 22.672 billion yuan [1]. - The stock has experienced a net outflow of 4.3243 million yuan in principal funds, with significant buying and selling activity from large orders [1]. - The stock has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on July 4, where it saw a net purchase of 87.5322 million yuan [1]. Shareholder Composition - As of September 30, 2025, the sixth-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 4.6168 million shares as a new shareholder [2]. - The seventh-largest shareholder is Southern CSI 500 ETF, which reduced its holdings by 93,400 shares [2]. - The tenth-largest shareholder is Innovation Drug, also a new entrant with 1.7893 million shares [2].

Core Viewpoint - Bid Pharma's stock price has shown a significant increase of 50.29% year-to-date, with a current market capitalization of 6.597 billion yuan, indicating strong investor interest and performance in the pharmaceutical sector [1][2]. Financial Performance - For the period from January to September 2025, Bid Pharma achieved a revenue of 979 million yuan, representing a year-on-year growth of 20.67%. The net profit attributable to shareholders was 120 million yuan, reflecting a substantial increase of 42.79% compared to the previous year [2]. - The company has distributed a total of 258 million yuan in dividends since its A-share listing [3]. Stockholder Information - As of September 30, 2025, the number of shareholders for Bid Pharma decreased by 7.64% to 3,493, while the average number of circulating shares per person increased by 8.27% to 12,377 shares [2]. - The top ten circulating shareholders include notable institutional investors, with China Europe Medical Health Mixed A being the second-largest shareholder, increasing its holdings by 20.07% [3]. Market Activity - On November 10, Bid Pharma's stock rose by 2.07%, trading at 72.59 yuan per share with a total transaction volume of 23.1378 million yuan. The stock has experienced a slight decline of 1.71% over the past five trading days but has shown a positive trend over longer periods [1].

Core Viewpoint - Kanghong Pharmaceutical's stock has shown significant volatility, with a year-to-date increase of 67.32%, but recent declines in the short term indicate potential market concerns [1][2]. Financial Performance - For the period from January to September 2025, Kanghong Pharmaceutical reported a revenue of 3.624 billion yuan, reflecting a year-on-year growth of 6.23%. The net profit attributable to shareholders was 1.033 billion yuan, with a growth of 6.08% compared to the previous year [2]. - The company has distributed a total of 2.038 billion yuan in dividends since its A-share listing, with 1.040 billion yuan distributed over the last three years [3]. Stock Market Activity - As of November 10, 2023, Kanghong Pharmaceutical's stock price was 31.79 yuan per share, with a market capitalization of 29.289 billion yuan. The stock experienced a trading volume of 147 million yuan and a turnover rate of 0.68% [1]. - The stock has seen a net outflow of 4.0184 million yuan from major funds, with significant buying and selling activity from large orders [1]. Shareholder Structure - As of October 20, 2023, the number of shareholders increased to 24,900, a rise of 3.53%. The average number of circulating shares per shareholder decreased by 3.41% to 27,592 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 28.007 million shares, an increase of 730,000 shares from the previous period [3].

Core Viewpoint - The stock of Jibeier has experienced a decline of 2.02% on November 10, with a current price of 31.01 CNY per share, despite a year-to-date increase of 41.73% [1] Financial Performance - For the period from January to September 2025, Jibeier achieved a revenue of 704 million CNY, representing a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million CNY, which is a 12.80% increase compared to the previous year [2] - Cumulative cash dividends since the A-share listing amount to 476 million CNY, with 252 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Jibeier is 7,742, an increase of 28.97% from the previous period, while the average circulating shares per person decreased by 22.46% to 25,759 shares [2] - The top ten circulating shareholders include new entrants such as Caitong Advantage Industry Rotation Mixed A and GF Healthcare Stock A, holding 1.2392 million shares and 959,000 shares respectively [3] Stock Market Activity - On November 10, Jibeier's trading volume reached 40.387 million CNY, with a turnover rate of 0.65% and a total market capitalization of 6.184 billion CNY [1] - The stock has seen a decline of 9.17% over the last five trading days, 6.60% over the last twenty days, and 1.30% over the last sixty days [1] Business Overview - Jibeier, established on November 13, 2001, and listed on May 18, 2020, is primarily engaged in the research, production, and sales of pharmaceuticals [1] - The main revenue sources include Likujun tablets (72.72%), Niqurol tablets (14.20%), Yupingfeng capsules (4.88%), and other products [1]

Core Viewpoint - Zai Jian Pharmaceutical has experienced a significant stock price increase of 55.48% year-to-date, despite recent declines in the last five, twenty, and sixty trading days [1][2]. Company Overview - Zai Jian Pharmaceutical, established on March 18, 2009, and listed on January 23, 2020, is located in Kunshan, Jiangsu Province. The company focuses on the research, production, and sales of chemical and biological new drugs, with 99.97% of its revenue derived from pharmaceuticals [1][2]. Financial Performance - For the period from January to September 2025, Zai Jian Pharmaceutical reported a revenue of 593 million yuan, reflecting a year-on-year growth of 54.49%. However, the net profit attributable to shareholders was a loss of 93.42 million yuan, which is an increase of 4.58% compared to the previous period [2]. Stock Market Activity - As of November 10, Zai Jian Pharmaceutical's stock price was 96.88 yuan per share, with a market capitalization of 25.645 billion yuan. The stock has seen a trading volume of 143 million yuan and a turnover rate of 0.57% [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent entry on October 31, where it recorded a net purchase of 187 million yuan [1]. Shareholder Information - As of September 30, 2025, Zai Jian Pharmaceutical had 8,809 shareholders, with an average of 30,049 circulating shares per shareholder. The top ten circulating shareholders include various mutual funds, with notable changes in holdings among some [2].

第一条 评奖宗旨 在港股市场强劲复苏、中国资产价值重估的背景下，此奖旨在表彰在高质量发展、高水平对外开放的历 史进程中，在制度创新和产业变革等方面展现出强大综合实力与前瞻性发展战略的港股上市公司。 第二条 评奖周期 中国证券报上市公司（港股）金牛奖评选工作，每年举办一届。 第三条 奖项设置 在行业遴选和奖项设置方面，着重呼应时代发展脉搏和产业发展方向，重点关注人工智能、新能源、新 材料和生物医药等前沿科技领域的创新突破，表彰在全球化背景下将业务、品牌和技术成功出海的标杆 企业，以及强调在追求商业成功的同时积极履行社会责任、重视股东回报、推动可持续发展的长期价值 的优秀典范。 上市公司（港股）金牛奖共四个大类、11个单项公司奖项，不设置个人奖项。其中，第一类：综合价值 与绩效类，包括卓越港股公司金牛奖、股东回报金牛奖和永续经营金牛奖；第二类：成长与创新类，包 括成长价值金牛奖、科技创新金牛奖、新消费标杆金牛奖和出海创新金牛奖；第三类：公司治理与社会 责任类（ESG），包括公司治理金牛奖、社会责任金牛奖和投资者关系金牛奖；第四类：港股IPO中介 机构金牛奖，涵盖保荐机构、审计机构、法律顾问和其他第三方服务机构。 ...

Core Viewpoint - The article discusses the development of high-tech zones in China, emphasizing their role as innovation hubs and the need for high-quality development in the context of the 2025 Torch Forum held in Xiong'an New Area, Hebei [1] Group 1: Innovation and Technology Supply - National high-tech zones are critical for industrial innovation, housing 70% of national manufacturing innovation centers and 80% of key laboratories, with companies contributing about 50% of national R&D funding and patents by the end of 2024 [2] - The changing environment during the 14th Five-Year Plan period necessitates a focus on high-level technological self-reliance and new industrialization, with a pressing need for collaboration among enterprises within high-tech zones [2] Group 2: Competitive High-Tech Industry Clusters - Development of industry clusters is vital for stabilizing and enhancing the industrial chain, with examples like Chengdu and Suzhou high-tech zones focusing on leading industries such as electronic information and biomedicine [3] - The Ministry of Industry and Information Technology aims to cultivate new trillion-yuan industry tracks by 2027, focusing on advanced technologies like AI, biomedicine, and low-carbon energy [3] Group 3: Technology Service Industry Development - The technology service industry is essential for efficient conversion of scientific achievements, providing services like R&D and consulting to support deep integration of technological and industrial innovation [4][5] - A comprehensive management service platform for national high-tech zones is being developed to enhance resource sharing and improve the efficiency of technology transfer [6] Group 4: Future Outlook and Strategic Initiatives - The Ministry of Industry and Information Technology plans to streamline technology transfer channels, foster quality technology service institutions, and create a favorable environment for industrial development during the 14th Five-Year Plan [6]